RaDVaC Data Explorer
Antiviral database
Virus Taxonomy
← Back to Dashboard
Daklinza+Sunvepra
NS3/4A protease inhibitor + NS5A inhibitor
Constituent drugs (2)
Daclatasvir
Loading structure...
3D not available
Asunaprevir
Loading structure...
3D not available
Chemical Identifiers
ClinicalTrials.gov
PubMed
Clinical Development by Virus
1
Hepatitis C virus
HCV
Target: Viral NS3/4A + NS5A
Approved (other)
Preclinical
Phase 2
positive
Phase 3
positive
Approved
Japan
Approval ref (pmda.go.jp)
PMDA approved Jul. 4, 2014
fixed-dose combination of Daclatasvir, Asunaprevir.